Related Links

Go Back

SNM Guidelines Neurology

Links are provided here to some Society of Nuclear Medicine (SNM) Practice Management - Procedure Guidelines. The procedure guidelines help to identify those elements of the procedure that are most important in obtaining a high-quality examination, while simultaneously controlling costs.

They are categorized in clinical applications. Please follow the links below to the desired applications. 

The purpose of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of [18F]FDG brain metabolic imaging. The document considers the work of previous guideline organizations such as the German Inter Disciplinary Consensus Conference on Clinical Brain PET, The Austrian Guideline for the Use of FDG-PET in Neurology and Psychiatry, The Society of Nuclear Medicine Procedure Guidelines for Tumor Imaging Using [18F]FDG, The Society of Nuclear Medicine Brain Imaging Council and by individual experts throughout the world.

The purpose of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of brain perfusion imaging to assist in confirming the diagnosis of brain death. Several 99mTc-labeled agents may be used, including 99mTc-ethyl cysteinate dimer (99mTc-ECD), 99mTc-hexamethylpropylene amine oxime (99mTc-HMPAO) and 99mTc-diethylenetriaminepentaacetic acid (99mTc-DTPA). 

The purpose of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of brain perfusion SPECT studies using 99mTc radiopharmaceuticals, such as unstabilized 99mTc-exametazime (HMPAO), stabilized 99mTc-HMPAO and 99mTc-bicisate (ethyl cystine dimer [ECD]).